文献速递冠心病血脂与心血管预防

普通拟杆菌与多氏拟杆菌减少肠道微生物脂多糖生成并抑制动脉粥样硬化

Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis.
PubMed 文献 · Circulation · 2018-01-01

研究比较冠心病患者与有冠脉危险因素但无冠心病对照者的粪便菌群,发现冠心病患者中普通拟杆菌和多氏拟杆菌丰度显著降低。在易患动脉粥样硬化小鼠中灌胃这两种活菌可减轻动脉粥样硬化病变、改善内毒素血症并抑制促炎免疫反应。冠心病患者粪便脂多糖水平显著升高且与这两种菌丰度负相关。

要点

  • 冠心病患者肠道普通拟杆菌和多氏拟杆菌丰度显著低于无冠心病对照。
  • 灌胃这两种活菌可减轻易患动脉粥样硬化小鼠的病变形成。
  • 冠心病患者粪便脂多糖升高,且与两种菌丰度负相关。

核心结论

  • 特定肠道细菌与动脉粥样硬化之间存在此前未知的联系。
  • 普通拟杆菌和多氏拟杆菌活菌治疗可能有助于预防冠心病。

研究设计与样本

  • 纳入冠心病患者与有冠脉危险因素但无冠心病的对照者,用16S rRNA基因测序比较粪便菌群。
  • 用易患动脉粥样硬化小鼠研究特定菌种与动脉粥样硬化关系的机制。
  • 临床试验注册号UMIN000015703。

主要发现

  • 人粪便16S rRNA基因测序显示冠心病患者普通拟杆菌和多氏拟杆菌丰度显著降低,并经定量聚合酶链反应确认。
  • 灌胃普通拟杆菌和多氏拟杆菌活菌可减轻易患动脉粥样硬化小鼠的动脉粥样硬化病变形成。
  • 灌胃这两种活菌明显改善内毒素血症,随后降低肠道微生物脂多糖生成并有效抑制促炎免疫反应。
  • 冠心病患者粪便脂多糖水平显著更高,且与普通拟杆菌和多氏拟杆菌丰度负相关。

临床怎么用

  • 普通拟杆菌和多氏拟杆菌活菌可能作为预防冠心病的候选干预方向。
  • 粪便脂多糖水平及这两种菌丰度或可作为与冠心病相关的微生物标志物用于研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is increasingly recognized that gut microbiota play a pivotal role in the development of atherosclerotic cardiovascular disease. Previously, we have reported that the abundance of genus Bacteroides is lower in patients with coronary artery disease (CAD) than in patients without CAD with coronary risk factors or in healthy volunteers. However, it remains unclear which and how specific gut bacteria contribute to the progression of atherosclerosis. METHODS: We recruited patients with CAD patients and controls without CAD with coronary risk factors. We then compared gut microbial composition using 16S ribosomal RNA gene sequencing in fecal samples to detect species with differential abundance between 2 groups. Subsequently, we used atherosclerosis-prone mice to study the mechanisms underlying the relationship between such species and atherosclerosis. RESULTS: Human fecal 16S ribosomal RNA gene sequencing revealed a significantly lower abundance of Bacteroides vulgatus and Bacteroides dorei in patients with CAD. This significant differential abundance was confirmed by quantitative polymerase chain reaction. Gavage with live B. vulgatus and B. dorei attenuated atherosclerotic lesion formation in atherosclerosis-prone mice, markedly ameliorating endotoxemia followed by decreasing gut microbial lipopolysaccharide production, effectively suppressing proinflammatory immune responses. Furthermore, fecal lipopolysaccharide levels in patients with CAD were significantly higher and negatively correlated with the abundance of B. vulgatus and B. dorei. CONCLUSIONS: Our translational research findings identify a previously unknown link between specific gut bacteria and atherosclerosis. Treatment with live B. vulgatus and B. dorei may help prevent CAD. CLINICAL TRIAL REGISTRATION: URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018051 . Unique identifier: UMIN000015703.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yoshida N, Emoto T, Yamashita T, et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation. 2018. PMID: 30571343. doi:10.1161/CIRCULATIONAHA.118.033714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。